MarketPulse

drug competition

3 articles
The Motley FoolThe Motley Fool··Lee Samaha

Novo Nordisk's Sickle Cell Win Decimates Agios Stock 23% in Single Day

Agios Pharmaceuticals plunged 23% after Novo Nordisk's superior sickle cell drug trial results overshadowed Agios' failed mitapavit candidate, threatening its commercial viability.
NVOAGIOFDA approvalclinical trial results
The Motley FoolThe Motley Fool··Reuben Gregg Brewer

Eli Lilly's GLP-1 Dominance Masks Valuation Risks for Long-Term Investors

$LLY dominates GLP-1 market with strong Mounjaro, Zepbound sales but trades at 40x P/E—well above pharma peers—raising concerns about priced-in perfection.
PFELLYNVOGLP-1 drugsZepbound
The Motley FoolThe Motley Fool··Reuben Gregg Brewer

Eli Lilly's GLP-1 Dominance Masks Valuation Risks for Long-Term Investors

Eli Lilly's GLP-1 success masks valuation risks; P/E of 44 leaves little room for competitive pressure and patent cliff execution.
PFELLYNVOGLP-1 drugsgeneric competition